Polish Psychiatric Association Guides Metabolic Risk Management in Antipsychotic Users

This PTP Part II update positions metformin and incretin-based agents as mainstream tools for preventing and treating antipsychotic-associated metabolic disease, directly relevant to pharmacists supporting psychiatric populations.

📅 Journal publication: Aug 30, 2026 · Last updated: Oct 12, 2026

★ Editor's PickPolish Psychiatric Association recommendations Part IIPolish Psychiatric Association (PTP)antipsychotic-induced metabolic disorders and obesitymetforminGLP-1 receptor agonistsdual GIP/GLP-1 agonist tirzepatideantipsychotics Psychiatry / Psychopharmacology

Also in Endocrinology / Obesity

Background Information

Prevent metabolic disorders in patients on antipsychotics with early screening and metformin.

Antipsychotics can increase the risk of obesity, diabetes, and metabolic disorders, requiring careful management. Recommendations emphasize early metabolic risk assessment and consideration of metformin for high-risk patients. Encourages pharmacists to monitor metabolic markers in patients taking antipsychotics and consider metformin as a preventive tool. Early intervention with metformin can prevent antipsychotic-induced metabolic disorders.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Wichniak A, Klupa T, Kuryłowicz A, Szulc A, Samochowiec J, Dudek D, Heitzman J, Cyranka K, Bieńkowski P

Citation: Wichniak A, Klupa T, Kuryłowicz A, et al. Reducing the risk of obesity, diabetes, and metabolic disorders in patients treated with antipsychotics - recommendations of the Polish Psychiatric Association Part II: diagnostics and pharmacological treatment. Psychiatria polska. 2026;60(4):565-580. doi:10.12740/PP/224831

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →